Data Integrity Challenges in Pharma Labs

The Billion-Dollar Blind Spot

A pharmaceutical company can spend years developing a drug, invest hundreds of millions in clinical trials, build manufacturing capacity, and reach the final stages of regulatory approval, only to face rejection because its records fail to demonstrate how critical data was generated. Data integrity in pharma is not simply a record-keeping requirement; it is the foundation of every regulatory submission, batch release, and quality decision. Even when the science is sound and test results are accurate, missing documentation, poor traceability, or inadequate audit trails can undermine trust in the data. Regulatory authorities including the FDA and EMA consistently emphasize that data integrity failures are systemic quality issues that can lead to warning letters, import bans, consent decrees, product recalls, and significant financial losses. As a result, pharmaceutical companies must implement structural data integrity solutions that ensure complete, accurate, and traceable records throughout the product lifecycle.

Data Integrity: ALCOA+ Explained

ALCOA+ is the globally accepted framework used by regulators including the FDA, EMA, MHRA, and WHO to evaluate data integrity in pharmaceutical laboratories. It defines nine principles that every compliant data record must meet: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available.

Attributable means every record must identify who created or modified it. Legible requires records to remain readable throughout their retention period. Contemporaneous means data must be recorded when it is generated, while Original requires preservation of the first capture of data. Accurate means records must reflect what was observed or measured.

Complete ensures that all data, including failed or invalid results, is retained. Consistent requires records to be logically coherent and free from discrepancies. Enduring means records must be securely preserved for the required retention period, and Available ensures they can be readily retrieved for review and inspection.

Together, these principles form the foundation of data integrity, ensuring that pharmaceutical data remains trustworthy, traceable, and suitable for regulatory review throughout the product lifecycle.

Where Pharma Data Integrity Fails

Audit Trail Gaps

Audit trail gaps are among the most common causes of data integrity in pharma findings. An audit trail that can be disabled, altered, or fails to capture critical activities such as deletions, modifications, or user actions cannot support regulatory compliance. Because regulators require complete audit trails, any missing information can make records non-compliant and undermine confidence in the associated data.

Raw Data Disconnect

A frequent data integrity challenge is the disconnect between reported results and the raw data that generated them. For example, an HPLC result may be recorded in a Laboratory Information Management System (LIMS) while the original chromatogram remains stored separately on an instrument workstation. Regulators expect raw data to remain unmodified, readily accessible, and directly linked to the official record to ensure traceability and data integrity in pharma.

Result Cherry-Picking

Result cherry-picking occurs when multiple test runs are performed but only favourable results are documented. This is one of the most serious data integrity violations because it compromises the scientific record and can impact patient safety. Regulatory requirements mandate that every test run, including failed or unexpected results, must be recorded and investigated through a documented process.

Change Control Failures

Change control failures occur when specifications, methods, instruments, or processes are modified without formal approval. Even minor undocumented changes can create compliance risks and compromise validated processes. Effective change control is essential for maintaining data integrity in pharma and ensuring compliance with regulations such as 21 CFR Part 211.

Pharma Informatics Solutions for Data Integrity

LIMS: Compliance by Design

The most effective response to data integrity in pharma is not more policies or training programs, but systems that make compliant behaviour the default. Qualis LIMS is designed to address pharmaceutical data integrity requirements through automated controls and traceability. Every user action, including result entry, modification, approval, rejection, login, and logout, is automatically captured in a tamper-proof audit trail with authenticated user details and timestamps. Role-based access controls ensure users can only perform actions permitted by their responsibilities, while electronic signatures support compliance with 21 CFR Part 11, EudraLex Annex 11, GxP, and ALCOA+ requirements.

Download LIMS brochure for full capabilities.

ELN: Contemporaneous Records

For pharmaceutical R&D laboratories, maintaining contemporaneous and traceable experimental records is essential for data integrity. Logilab ELN replaces paper notebooks with a structured digital environment where every entry is automatically timestamped and linked to the authenticated user. Protocol versions are controlled, experimental activities are fully documented, and data can transfer directly to Qualis LIMS without manual re-entry. This eliminates transcription errors and strengthens traceability, accuracy, and compliance across research workflows.

SDMS: Original Data Preserved

Logilab SDMS addresses one of the most common data integrity gaps in pharmaceutical laboratories: disconnected raw data. The system automatically captures and archives raw instrument files such as chromatograms, spectra, dissolution curves, and particle size data from multiple instruments and vendors. Every file is securely stored with metadata and linked to the associated sample, analyst, instrument, and result record in Qualis LIMS. This ensures original data remains accessible, unmodified, and readily available for audits, inspections, and regulatory review.

DMS: Document Control

Document management plays a critical role in maintaining data integrity in pharma. Qualis DMS provides centralized control of SOPs, analytical methods, specifications, validation protocols, and quality documents through version control and approval workflows. Only approved document versions are available for active use, while previous versions are archived for audit purposes. Electronic acknowledgments ensure that personnel have reviewed and accepted current procedures, reducing compliance risks associated with outdated or unauthorized documents.

Learn more about Paperless Pharma Labs

Conclusion

Staying Audit Ready

Data integrity in pharma is not a compliance checkbox or a concern that surfaces only during regulatory inspections. It is the foundation of regulatory trust, product quality, and patient safety. Laboratories that build their operations around ALCOA+ principles and a connected laboratory informatics ecosystem can ensure that data is attributable, contemporaneous, original, accurate, complete, consistent, enduring, and available by design. In this environment, audit readiness becomes a continuous operational state rather than a periodic compliance exercise.

By integrating LIMS, ELN, SDMS, and DMS into a unified platform, pharmaceutical organizations can strengthen data integrity, improve traceability, and simplify regulatory compliance across the entire data lifecycle. When inspectors request evidence, the complete record and supporting documentation can be retrieved instantly, reducing compliance risks and improving confidence in laboratory data.

Discover how Agaram's integrated laboratory informatics ecosystem helps pharmaceutical organizations strengthen data integrity, maintain ALCOA+ compliance, and stay audit-ready. Book a personalized pharma informatics demo with our experts today.